Metoprolol vs Atenolol
Overview
Metoprolol and atenolol are both cardioselective beta-1 adrenergic receptor antagonists widely used for hypertension, angina, and heart failure. Key differences include their lipophilicity, CNS penetration, metabolism, and outcome data in heart failure.
Mechanism of Action
Both competitively block beta-1 adrenoceptors, reducing heart rate, myocardial contractility, and blood pressure. At standard doses, both are relatively selective for beta-1 over beta-2 receptors, minimizing bronchospasm risk. This selectivity diminishes at high doses.
Pharmacokinetics
Metoprolol is highly lipophilic, extensively absorbed (bioavailability ~50% immediate-release due to first-pass metabolism), and metabolized by CYP2D6. Genetic polymorphisms in CYP2D6 significantly alter metoprolol plasma levels β poor metabolizers can have 5-fold higher exposure. Metoprolol crosses the blood-brain barrier readily. Half-life 3β7 h (immediate-release) or 12β24 h (extended-release XL).
Atenolol is hydrophilic, absorbed ~50%, minimally metabolized (80β90% excreted unchanged by kidneys), and has a half-life of 6β9 h. It does not cross the blood-brain barrier significantly.
Pharmacodynamics and Clinical Evidence
Both provide effective antihypertensive and antianginal effects. However, a critical pharmacological distinction exists: the MERIT-HF trial demonstrated that metoprolol succinate XL significantly reduces mortality in heart failure with reduced ejection fraction (HFrEF), establishing it as one of three beta-blockers with proven mortality benefit in HF (alongside carvedilol and bisoprolol). Atenolol lacks this evidence for HFrEF.
The ASCOT-BPLA trial raised concerns that atenolol was inferior to amlodipine-based therapy for cardiovascular prevention, partly due to less effective 24-h BP control and potentially unfavorable metabolic effects. Metoprolol XL, not atenolol, is guideline-recommended for HF.
Renal Impairment
Atenolol requires dose reduction in renal impairment (CrCl <35 mL/min) as it is renally eliminated. Metoprolol does not require renal dose adjustment.
CNS Effects
Metoprolol's lipophilicity allows CNS penetration, which may contribute to side effects such as fatigue, depression, and sleep disturbances. Atenolol causes fewer CNS-related adverse effects.
Key Takeaways
- Both cardioselective beta-1 blockers with similar antihypertensive efficacy
- Metoprolol XL: proven mortality benefit in HFrEF (MERIT-HF); atenolol lacks this
- Atenolol: renally cleared, dose reduce in CKD; metoprolol: CYP2D6 metabolized
- Atenolol causes fewer CNS side effects due to hydrophilicity
Verdict
Metoprolol succinate XL is preferred over atenolol in heart failure with reduced ejection fraction (evidence-based, MERIT-HF). For uncomplicated hypertension, both are comparable though atenolol is less preferred in guideline updates. Atenolol may be chosen in patients with significant CNS sensitivity to beta-blockers.